Please assess the completion status of the following clinical trial:

Trial Title: Study of Orofacial Pain and PropRANOlol

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion:~* Diagnostic criteria for TMD: Group II, Masticatory Muscle Disorders, Myalgia~* Facial pain for at least 3 months (and at least 10 of the last 30 days at Visit 0)~* Average pain intensity rating ≥30 (0-100 numeric rating scale) over the past week or average daily pain intensity rating ≥30 on the same scale on at least 3 days over the past week~* Agrees to terms for continuing/discontinuing certain prescription/over-the-counter pain medications throughout participation~* Agrees to not commence new prescription medication, injection therapy, occlusal splint therapy or certain other pain management techniques throughout participation~* Agrees to limit consumption of alcohol to no more than 7 drinks/week (females) and no more than 14 drinks/week (males) throughout participation~* If a female of childbearing potential, agrees to use of contraception (licensed hormonal method, intrauterine device, condoms with contraceptive foam, abstinence, or partner vasectomy) throughout participation~* Able to understand and comply with study procedures and provide written informed consent~Exclusion:~* History of congestive heart failure or certain cardiac conditions including coronary artery disease, uncontrolled hypertension, or hypotension~* Bronchial asthma, nonallergic bronchospasm, renal failure or dialysis, diabetes mellitus, hyperthyroidism, fibromyalgia, or uncontrolled seizures~* Currently taking a β-blocker or certain other medications including haloperidol, intravenous verapamil, or reserpine~* Currently taking an opioid medication~* Daily prescription medication, occlusal splint therapy, or an investigational drug or treatment for pain management within past 30 days~* Injection therapy or certain other pain management techniques within last 2 weeks~* Facial trauma or orofacial surgery within past 6 weeks~* Active orthodontic treatment~* History of major depression or other psychiatric disorder requiring hospitalization within past 6 months~* Treatment for drug or alcohol abuse within the last year~* Smokes 25 or more cigarettes/day~* Currently receiving chemotherapy or radiation therapy~* Pregnant or breastfeeding

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Study Arms:
- Propranolol ER (Type: ACTIVE_COMPARATOR): Propranolol hydrochloride extended release (ER) capsules; 60 mg (Visit 1 and Visit 4); 120 mg (Visit 2 and Visit 3) given orally as: 60 mg once/day (Visit 1 and Visit 4) and 60 mg twice/day (Visit 2 and Visit 3).
- Placebo (Type: PLACEBO_COMPARATOR): Capsules, identical in appearance to active comparator (propranolol), to be administered orally in exactly the same manner as propranolol at Visit 1 (once/day), Visit 2 (twice/day), Visit 3 (twice/day), and Visit 4 (once/day).

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete